How To Test For Platelet Function
|
|
|
- Hilary Kelly
- 5 years ago
- Views:
Transcription
1 Platelet function in thrombocytopenia Mark Roest Synapse Research Institute, Maastricht
2 No Disclosures
3 Trauma
4 1. Adhesion
5 2. Activation and Aggregation
6 3. Stable Aggregate Formation
7 4. Repair
8 Platelet Disorder Mucocutaneous bleeding low platelet count and/or dysfunction epistaxis Prolonged bleeding Heavy Bruising Petechiae Gastro-intestinal bleeding Oral bleeding Bleeding after tooth extraction Menorrhagia
9 Thrombocytopenia: Current guidelines Platelet counts < 10*10 9 platelets / L transfusion Platelet counts > 10*10 9 platelets / L no transfusion We need platelet function testing in addition to platelet counts Those patients don t need transfusion if the function of the remaining platelets is still adequate Those patients need transfusion if the function of the remaining platelets is not adequate
10 Platelet function monitoring in diagnostic settings Bleeding time PFA-100 ROTEM TEG verifynow multiplate LTA These tests are based on platelet aggregation or platelet deposition This is highly dependent on platelete concentration
11 Platelet function tests Bleeding Time and PFA: Only for VW diseases and platelet adhesion ROTEM: Only for prediction post surgery bleeding? VASP: Only for P2Y12 inhibitor monitoring VerifyNOW: Only for P2Y12 inhibitors and aspirin monitoring Multiplate: Potentially interesting no progression Aggregometry: Gold standard disappearing Whole blood platelet function flow cytometry
12 SSC Count Count Platelet Function Agonist Anti-P-selectin P-selectine αiibβ Anti-fibrinogeen FSC CD62P-PE CD62P-PE
13 Platelet Activation Test (PACT) TRAP ADP Thrombin receptor (PAR1) ADP receptor (P 2 Y 12 ) Blood Platelet Collagen receptor (GPVI) CRP P-selectin (MFI) Flow Cytometry ADP ( TRAP ( M) CRP(ng/mL) P-selectin (MFI) Master Mix P-selectin (MFI)
14 Platelet Activation Test (PACT) 1. Platelet function in stored concentrates 2. Platelet function in blood of patients with thrombocytopenia
15 Platelet Function in stored concentrates (1) P-selectin expression Day Time Days Middelburg RA, Roest M, Ham J, Coccoris M, Zwaginga JJ, van der Meer PF. Flow cytometric assessment of agonist-induced P-selectin expression as a measure of platelet quality in stored platelet concentrates. Transfusion Aug;53(8):
16 Platelet Function in stored concentrates (2) Time Days Cécile H. Kicken, Mark Roest, Yvonne M. Henskens, Bas de Laat, Dana Huskens. Monitoring platelet concentrates, submited
17 Platelet Function in stored concentrates (3) Time Days P-selectin expression (AU) SFLLRN Day a IIb b 3 activation (AU) SFLLRN Day P-selectin expression (AU) CRP Day a IIb b 3 activation (AU) CRP Day P-selectin expression (AU) ADP Day a IIb b 3 activation (AU) ADP Day P-selectin expression (AU) U Day a IIb b 3 activation (AU) U Day Roest M, van Holten TC, Fleurke GJ, Remijn JA. Platelet Activation Test in Unprocessed Blood (Pac-t-UB) to Monitor Platelet Concentrates and Whole Blood of Thrombocytopenic Patients. Transfus Med Hemother Apr;40(2):
18 Platelet Activation Test (PACT) 1. Platelet function in stored concentrates 2. Platelet function in blood of patients with thrombocytopenia
19 Platelet function in blood of patients with thrombocytopenia Healthy controls (n=10) Patients with thrombocytopenia (n=11) Bikker A, Bouman E, Sebastian S, Korporaal SJ, Urbanus RT, Fijnheer R, Boven LA, Roest M. Functional recovery of stored platelets after transfusion. Transfusion May;56(5):
20 P -s e le c tin e x p re s s io n (% ) P A R - 1 P A R - 4 C R P A D P P la te le t c o u n t (x /L ) Birol Batman, Esther R van Bladel, Mariska van Hamersveld, Pieternel CM Pasker-de Jong, Suzanne JA Korporaal, Rolf T Urbanus, Mark Roest, Leonie A Boven, Rob Fijnheer. Agonist induced platelet reactivity predicts bleeding in hemato-oncological patient, submited
21 Platelet function pre- and post-transfusion Bikker A, Bouman E, Sebastian S, Korporaal SJ, Urbanus RT, Fijnheer R, Boven LA, Roest M. Functional recovery of stored platelets after transfusion. Transfusion May;56(5):
22 M F I P -s e le c tin (u n its ) Platelet function, platelet count and bleeding risk Platelet function and bleeding Platelet count and bleeding P A R 1 -A P P A R 4 -A P * M F I P -s e le c tin (u n its ) ** 0 0 N o B le e d in g B le e d in g N o B le e d in g B le e d in g Birol Batman, Esther R van Bladel, Mariska van Hamersveld, Pieternel CM Pasker-de Jong, Suzanne JA Korporaal, Rolf T Urbanus, Mark Roest, Leonie A Boven, Rob Fijnheer. Agonist induced platelet reactivity predicts bleeding in hemato-oncological patient, submited
23 ITP Auto-antibodies to platelets Increased Platelet Consumption Low Platelet Counts ITP has a heterogeneous pathogenesis and the phenotype does not necessarily correlate with platelet counts Platelet Function Testing to customize the therapy?
24 Platelet function testing in ITP van Bladel, Laarhoven AG, van der Heijden LB, Heitink-Pollé KM, Porcelijn L, van der Schoot CE, de Haas M, Roest M, Vidarsson G, de Groot PG, Bruin MCFunctional platelet defects in children with severe chronic ITP as tested with 2 novel assays applicable for low platelet counts. Blood 2014;123:
25 Conclusion PACT can be used to monitor platelet function in concentrates PACT can be used to measure platelet function in thrombocytopenia Upcoming studies will show if this test can be used to customize the treatment of patients with thrombocytopenia
26 Mark Roest Philip de Groot Dana Huskens Bas de Laat Rob Fijnheer Leonie Boven Esther van Bladel Birol Batman Rolf Urbanus Suzanne Korporaal Albert Huisman Angela Bikker Jaap Jan Zwaginga Rutger Middelburg Jasper Remijn
Platelet Review July 2012. Thomas S. Kickler M.D. Johns Hopkins University School of Medicine
Platelet Review July 2012 Thomas S. Kickler M.D. Johns Hopkins University School of Medicine Hemostasis Hemostasis is the process that leads to the stopping of bleeding Hemostasis involves blood vessels,
Platelet storage pool disease case discussions. Tzu-Fei Wang The Hemostasis and Thrombosis Center The Ohio State University
Platelet storage pool disease case discussions Tzu-Fei Wang The Hemostasis and Thrombosis Center The Ohio State University Case I 29 yo WF presented for evaluation of possible platelet storage pool disease,
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY DEVICE AND INSTRUMENT TEMPLATE
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY DEVICE AND INSTRUMENT TEMPLATE A. 510(k) Number: K041502 B. Purpose for Submission: To change the name of a previously cleared analyzer, and
Bleeding disorders or haemorrhagic diatheses are a group of disorders characterised by defective haemostasis with abnormal bleeding.
Bleeding disorders or haemorrhagic diatheses are a group of disorders characterised by defective haemostasis with abnormal bleeding. Bleeding may be spontaneous in the form of small haemorrhages into the
Platelet Function analysis using Multiple Electrode Aggregometry (Multiplate )
Platelet Function analysis using Multiple Electrode Aggregometry (Multiplate ) Multiplate platelet function analysis in whole blood based on impedance aggregometry Multiplate instrument 5 channels for
Platelet Transmission Electron Microscopy and Flow Cytometry 11/15/2015
Welcome to Mayo Medical Laboratories Hot Topics. These presentations provide short discussion of current topics and may be helpful to you in your practice. Today our topic looks at hereditary platelet
Screening Tests of Platelet Function: Update on their appropriate uses for diagnostic testing
Screening Tests of Platelet Function: Update on their appropriate uses for diagnostic testing Paul Harrison Oxford Haemophilia & Thrombosis Centre Churchill Hospital Oxford, UK 10 th February 2011 Namur
Evaluation of the Patient with Suspected Platelet Refractory State
Evaluation of the Patient with Suspected Platelet Refractory State NOTE: While evaluating the patient for suspected immune refractory state provide ABO matched platelets if available. 1. Determine if the
Hemostasis analyzer system
Hemostasis analyzer system Providing fast, actionable results to help you reduce risks, complications and costs Get the whole picture with TEG Hemostasis analyzer system For more than forty years, hospitals
Multiplate platelet function analysis - application and interpretation
Dr. Andreas Calatzis PD Dr. Michael Spannagl Department for Haemostasis and Transfusion Medicine Munich University Clinic Ludwig-Maximilians University Ziemssen Str. 1 80336 Munich, Germany [email protected]
Rational for secondary prophylaxis in VWD
Rational for secondary prophylaxis in VWD Susan Halimeh Medical Thrombosis and Haemophilia treatment Center, Duisburg, Germany Dr. med. Susan Halimeh When is prophylaxis in patients with VWD recommended?
Embedding Point of Care monitoring (ROTEM) in daily practice
Embedding Point of Care monitoring (ROTEM) in daily practice Yvonne Henskens Clinical chemist Head of unit General Hematology, Hemostasis and Transfusion Central Diagnostic Laboratory Road to ROTEM 2009
Learning Objectives. Qualitative and Quantitative Platelet Disorders. Platelet Signaling. Platelet vs. Coagulation Bleeding.
Learning Objectives Qualitative and Quantitative Platelet isorders Jeffrey S. Jhang, M.. Assistant Professor of Clinical Pathology College of Physicians and Surgeons New York, New York Understand the evaluation
Point-of-care testing Thrombelastography and platelet transfusion
Point-of-care testing Thrombelastography and platelet transfusion Gisela Scharbert Department of Anesthesiology, Intensive Care and Pain Management Vienna Medical University, Austria Trauma-induced coagulopathy
Easy Bruising and Bleeding in the Adult Patient: A Sign of Underlying Disease
Review of Clinical Signs Series Editor: Bernard M. Karnath, MD Easy Bruising and Bleeding in the Adult Patient: A Sign of Underlying Disease Bernard M. Karnath, MD Achief complaint of easy bruising and
The author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 [email protected] This presentation will discuss unlabeled and investigational use of products The author
An Introduction to the Improved FDA Prescription Drug Labeling
An Introduction to the Improved FDA Prescription Drug Labeling 1 Introduction Mary E. Kremzner, Pharm.D. CDR, U.S. Public Health Service Deputy Director, Division of Drug Information Center for Drug Evaluation
ECG may be indicated for patients with cardiovascular risk factors
eappendix A. Summary for Preoperative ECG American College of Cardiology/ American Heart Association, 2007 A1 2002 A2 European Society of Cardiology and European Society of Anaesthesiology, 2009 A3 Improvement,
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY A. 510(k) Number: k103555 B. Purpose for Submission: New submission C. Measurand: Platelet aggregation D. Type of Test: Platelet aggregometer
Note: Page numbers in italics indicate figures. Page numbers followed by a t indicate tables.
INDEX Note: Page numbers in italics indicate figures. Page numbers followed by a t indicate tables. Acquired bleeding disorders, 37-57 acquired combined inhibitor to factor V and thrombin, 55 acquired
LABORATORY DIAGNOSIS OF BLEEDING DISORDERS
LABORATORY DIAGNOSIS OF BLEEDING DISORDERS Secondary Hemostasis CIRCULATORY SYSTEM Low volume, high pressure system Efficient for nutrient delivery to tissues Prone to leakage 2º 2 to endothelial surface
An overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham
An overview of CLL care and treatment Dr Dean Smith Haematology Consultant City Hospital Nottingham What is CLL? CLL (Chronic Lymphocytic Leukaemia) is a type of cancer in which the bone marrow makes too
chronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute
Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical
Guidelines for the Laboratory Investigation of Heritable Disorders of Platelet Function
Guidelines for the Laboratory Investigation of Heritable Disorders of Platelet Function British Committee for Standards in Haematology Writing group: Paul Harrison 1, Ian Mackie 2, Andrew Mumford 3, Carol
Annals of West University of Timisoara
Annals of West University of Timisoara Series of Chemistry 20 (1) (2011) 47-58 LABORATORY TESTING OF PLATELET FUNCTION BY AGGREGOMETRY: WHAT TEST SHOULD BE USED? Daniela Maximov a, Alina Lupu a, Cristiana
De effecten van Cofact op Rivaroxaban plasma in trombine generatie assays
De effecten van Cofact op Rivaroxaban plasma in trombine generatie assays In vitro assessment, using thrombin generation, of the applicability of Prothrombin Complex Concentrate as an antidote for Rivaroxaban
Guidance for Industry and FDA Review Staff on Collection of Platelets by Automated Methods
Guidance for Industry and FDA Review Staff on Collection of Platelets by Automated Methods Blood Products Advisory Committee, March 9, 2006 Steven Kleinman, MD Senior Medical Advisor, AABB Co-chair, AABB
Platelet Aggregation Testing in Platelet-Rich Plasma Description of Procedures With the Aim to Develop Standards in the Field
Coagulation and Transfusion Medicine / PLATELET FUNCTION TESTING Platelet Aggregation Testing in Platelet-Rich Plasma Description of Procedures With the Aim to Develop Standards in the Field Lan Zhou,
Recommendations: Other Supportive Therapy of Severe Sepsis*
Recommendations: Other Supportive Therapy of Severe Sepsis* K. Blood Product Administration 1. Once tissue hypoperfusion has resolved and in the absence of extenuating circumstances, such as myocardial
GUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY
BLOOD CONSERVATION STRATEGIES IN CARDIAC SURGERY: MORE IS BETTER GUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY DIMITRIOS V. AVGERINOS MD, PhD, FACS, FACC Department of Cardiac Surgery,
Management of the new antiplatelets and anticoagulants
Management of the new antiplatelets and anticoagulants Session No.: 1 Name: C. Boustiere, T Ponchon Guidelines : Anti-thrombotic agents and digestive endoscopy 2006 : French guideline (SFED) 2007 : Japanese
Omega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9
Omega-3 fatty acids improve the diagnosis-related clinical outcome 1 Critical Care Medicine April 2006;34(4):972-9 Volume 34(4), April 2006, pp 972-979 Heller, Axel R. MD, PhD; Rössler, Susann; Litz, Rainer
C HAPTER 4 O RAL AND M AXILLOFACIAL S URGERY
C HAPTER 4 O RAL AND M AXILLOFACIAL S URGERY I. TREATMENT PLANNING GUIDELINES As part of informed consent, the clinician should carefully explain the risks and benefits of oral and maxillofacial surgery
ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head
ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY Dr. Mahesh Vakamudi Professor and Head Department of Anesthesiology, Critical Care and Pain Medicine Sri Ramachandra University INTRODUCTION
Whole Blood Flow Cytometry
Whole Blood Flow Cytometry y Nailin Li Department t of Medicine, i Clinical i l Pharmacology Unit Karolinska Institute/University Hospital, 171 76 Stockholm Department of Pathology & Pathophysiology Zhejiang
Review of Newer Antiplatelets, Antithrombotics and Reversal
Review of Newer Antiplatelets, Antithrombotics and Reversal Ravi Sarode, MD Professor of Pathology Chief of Pathology and Medical Director of Clinical Laboratory Services Director, Transfusion Medicine
Immune Thrombocytopenic Purpura (ITP): A New Look at an Old Disorder
Spring 2010 Immune Thrombocytopenic Purpura (ITP): A New Look at an Old Disorder INTRODUCTION: What is ITP? ITP, Immune Thrombocytopenic Purpura, is an acquired bleeding disorder in which the immune system
Grade 4 Thrombocytopenia During. Predictor of Response in Melanoma but Not in Renal Cell Cancer.
Grade 4 Thrombocytopenia During Treatment with High-Dose IL-2 2 (HD IL-2) is a Predictor of Response in Melanoma but Not in Renal Cell Cancer. Timothy E. Bael, M.D. Bercedis L. Peterson, Ph.D. Karima Rasheed,
Predictive power. Multiplate analyzer
Predictive power Multiplate analyzer Multiplate analyzer Strengthening Roche s hemostasis portfolio With a series of industry firsts and innovative applications for early disease detection and monitoring,
Indications 18 : PLATELET TRANSFUSION, ALLOIMMUNIZATION AND MANAGEMENT OF PLATELET REFRACTORINESS
18 : PLATELET TRANSFUSION, ALLOIMMUNIZATION AND MANAGEMENT OF PLATELET REFRACTORINESS Alan Tinmouth Platelets are the smallest of the blood cells, with a diameter of 2 3 µm and no nucleus. Their function
The Monocyte Monolayer Assay (MMA): An Adjunct to Compatibility Testing
The Monocyte Monolayer Assay (MMA): An Adjunct to Compatibility Testing Ghislain Noumsi MD,SBB(ASCP) CM Molecular ImmunoHematologist Scientific Support Services LifeShare Blood Centers Shreveport, LA Objectives
DATE: 06 May 2013 CONTEXT AND POLICY ISSUES
TITLE: Low Molecular Weight Heparins versus New Oral Anticoagulants for Long-Term Thrombosis Prophylaxis and Long-Term Treatment of DVT and PE: A Review of the Clinical and Cost-Effectiveness DATE: 06
INTRODUCTION Thrombophilia deep vein thrombosis DVT pulmonary embolism PE inherited thrombophilia
INTRODUCTION Thrombophilia (Hypercoagulability) is a condition in which a person forms blood clots more than normal. Blood clots may occur in the arms or legs (e.g., deep vein thrombosis DVT), the lungs
Strong bone for beautiful teeth Patient Information I Bone reconstruction with Geistlich Bio-Oss and Geistlich Bio-Gide
Strong bone for beautiful teeth Patient Information I Bone reconstruction with Geistlich Bio-Oss and Geistlich Bio-Gide Contents Smiling is the most beautiful way to show your teeth 3 What are the causes
Is There A LIfe for DES after discontinuation of Clopidogrel
Chicago 2014 Is There A LIfe for DES after discontinuation of Clopidogrel Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin:
Issues and Challenges in ACS Management. Dr.Nakul Sinha MD.DM, FACC. Sahara Hospital, LUCKNOW
1 Issues and Challenges in ACS Management Dr.Nakul Sinha MD.DM, FACC. Sahara Hospital, LUCKNOW 2 Disclaimer Presentation are intended for educational purposes only and do not replace independent professional
INTRODUCTION Thrombophilia deep vein thrombosis DVT pulmonary embolism PE inherited thrombophilia
INTRODUCTION Thrombophilia (Hypercoagulability) is a condition in which a person forms blood clots more than normal. Blood clots may occur in the arms or legs (e.g., deep vein thrombosis DVT), the lungs
Update on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD
Update on Antiplatelets and anticoagulants Timir Paul, MD, PhD Antiplatelets Indications Doses Long term use (beyond 12 months) ASA and combination use of NSAIDS ASA resistance Plavix resistance Plavix
SARASOTA MEMORIAL HOSPITAL BLOOD COMPONENT CRITERIA AND INDICATIONS SCREENING GUIDELINES
SARASOTA MEMORIAL HOSPITAL BLOOD COMPONENT CRITERIA AND INDICATIONS SCREENING GUIDELINES TABLE OF CONTENTS SUBJECT PAGE ADULT CRITERIA Red Blood Cells/Autologous 2 Washed Red Blood Cells 2 Cryoprecipitate
Use of Novel Oral Anticoagulants (NOACs) and the new DAWN modules at Scripps
Use of Novel Oral Anticoagulants (NOACs) and the new DAWN modules at Scripps Cheryl Ea, Pharm D. Anticoagulation Services Scripps Clinic and Scripps Green Hospital La Jolla, California Pharmacist Management
Yvette Marie Miller, M.D. Executive Medical Officer American Red Cross October 20, 2012 45 th Annual Great Lakes Cancer Nursing Conference Troy, MI
Yvette Marie Miller, M.D. Executive Medical Officer American Red Cross October 20, 2012 45 th Annual Great Lakes Cancer Nursing Conference Troy, MI Overview of Hematology, http://www.nu.edu.sa/userfiles/mhmorsy/h
New Anticoagulants: When and Why Should I Use Them? Disclosures
Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia
Disclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU
New Agents for Treatment of DVT Disclosure PI Adopt and Amplify trials Mark Oliver, MD, RVT, RPVI,FSVU BMS and Pfizer Speaker VTE Venous Thromboembolism Recognized DVT s New : 170,000 Recurrent : 90,000
Anticoagulants for stroke prevention in atrial fibrillation Patient frequently asked questions
Anticoagulants for stroke prevention in atrial fibrillation Patient frequently asked questions What is atrial fibrillation?...2 What are dabigatran, rivaroxaban and apixaban and what are they used for?...2
Genomic Analysis of Mature B-cell Malignancies
Genomic Analysis of Mature B-cell Malignancies Update and Lessons Learned Omar Abdel-Wahab, MD Memorial Sloan Kettering Cancer Center Human Oncology and Pathogenesis Program and Leukemia Service Disclaimer:
Abnormal Uterine Bleeding. Howard Herrell, MD FACOG
Abnormal Uterine Bleeding Howard Herrell, MD FACOG Disclosures I, Howard Herrell, DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a
Guideline Statement for the Treatment of Disseminated Intravascular Coagulation
Guideline Statement for the Treatment of Disseminated Intravascular Coagulation Introduction Though a rare occurrence in the perioperative setting, disseminated intravascular coagulation (DIC) is a syndrome
New Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
Heparin Induced Thrombocytopenia
Heparin Induced Thrombocytopenia Ann-Marie Liberman B.Sc.Phm., ACPR Clinical Pharmacist, Cardiac Surgery Clinical Trials Pharmacist Royal Columbian Hospital Fraser Health Disclosure Participated in research
Rheumatic Fever Vs. (?) Post Strep Reactive Arthritis ינואר 2009
Rheumatic Fever Vs. (?) Post Strep Reactive Arthritis ינואר 2009 Agenda Introduction Articles Poststreptococcal reactive arthritis in children: is it really a different entity from rheumatic fever? Poststreptococcal
Duration of Dual Antiplatelet Therapy After Coronary Stenting
Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are
University of Utah CME Statement
University of Utah CME Statement The University of Utah School of Medicine adheres to ACCME Standards regarding industry support of continuing medical education. Speakers are also expected to openly disclose
Platelet function defects
Haemophilia (2008), 14, 1240 1249 DOI: 10.1111/j.1365-2516.2008.01898.x ORIGINAL ARTICLE Platelet function defects D. SIMON,* T. KUNICKI and D. NUGENT* *From the ChildrenÕs Hospital of Orange County, Orange;
Prevention of Acute COPD exacerbations
December 3, 2015 Prevention of Acute COPD exacerbations George Pyrgos MD 1 Disclosures No funding received for this presentation I have previously conducted clinical trials with Boehringer Ingelheim. Principal
Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction
Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction Esther Lopez Garcia, Matthias B Schulze, Teresa T Fung, James B Meigs, Nader Rifai, JoAnn
Periodontal Screening and Recording: Early Detection of Periodontal Diseases
Periodontal Screening and Recording: Early Detection of Periodontal Diseases Tanya Villalpando Mitchell, RDH, MS Continuing Education Units: 1 hour Online Course: www.dentalcare.com/en-us/dental-education/continuing-education/ce53/ce53.aspx
Enoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants
Enoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants Traffic light classification- Amber 2 Information sheet for Primary Care Prescribers Relevant Licensed Indications
Abnormal Basic Coagulation Testing Laboratory Testing Algorithms
Global Coagulation Testing Abnormal Basic Coagulation Testing Laboratory Testing Algorithms Jeffrey S. Jhang, M.D. No single global laboratory test Bleeding history is the strongest predictor of bleeding
The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012
The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era CCRN State of the Heart 2012 June 2, 2012 Disclosures I have I have been involved in trials of new anticoagulants and have received
Now We Got Bad Blood: New Anticoagulant Reversal
Now We Got Bad Blood: New Anticoagulant Reversal Kellie Rodriguez, PharmD, BCPS PGY2 Emergency Medicine Pharmacy Resident UF Health Jacksonville January 2016 Objectives 1. Review current treatment strategies
Traveller s Thrombosis. Dr. Peter Verhamme Vascular Medicine and Haemostasis UZ Leuven
Traveller s Thrombosis Dr. Peter Verhamme Vascular Medicine and Haemostasis UZ Leuven Case 1: To thromboprophylaxe or not Women, aged 49, BMI 29, Combined Oral Contraceptives. Family history of provoked
Canine Distemper Virus
Canine Distemper Virus Canine Distemper (CD) is a highly contagious infectious disease of dogs worldwide caused by the canine distemper virus (CDV). It is often fatal. CD is a multisystemic disease that
How To Know If You Have A Bleeding Disorder
WHAT ARE RARE CLOTTING FACTOR DEFICIENCIES? Published by the World Federation of Hemophilia (WFH) World Federation of Hemophilia, 2009 The WFH encourages redistribution of its publications for educational
CF ATLANTA Research & Development Program at Emory University and Georgia Tech (CF@LANTA) Clinical & Translational Research Core
CF ATLANTA Research & Development Program at Emory University and Georgia Tech (CF@LANTA) Clinical & Translational Research Core Arlene Stecenko, MD Director, Emory + Children s Cystic Fibrosis Care Center
Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab
Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 28, 2015 2:30 pm I have no disclosures. Stroke risk reduction in
Testing antiplatelet therapy
European Heart Journal Supplements (2008) 10 (Supplement A), A28 A34 doi:10.1093/eurheartj/sum081 Testing antiplatelet therapy Christian Gachet* and Boris Aleil INSERM U311 Unit, Etablissement Français
Bleeding Disorders What Every ER RN Should KNOW! Sherry Purcell, RN Hemophilia Nurse Specialist/EMERGENCY RN Kingston General Hospital
Bleeding Disorders What Every ER RN Should KNOW! Sherry Purcell, RN Hemophilia Nurse Specialist/EMERGENCY RN Kingston General Hospital 1 Canada s Inherited Bleeding Disorder Centres 26 Hemophilia A, B
Patient Guide. Important information for patients starting therapy with LEMTRADA (alemtuzumab)
Patient Guide Important information for patients starting therapy with LEMTRADA (alemtuzumab) This medicinal product is subject to additional monitoring. This will allow quick identification of new safety
New anticoagulants: Monitoring or not Monitoring? Not Monitoring
The 2 nd World Congress on CONTROVERSIES IN HEMATOLOGY (COHEM) Barcelona, Spain September 6 8, 2012 New anticoagulants: Monitoring or not Monitoring? Not Monitoring Anna Falanga, MD Immunohematology and
Instructions for Use
PN 14438.A.1 2012 09 14 Instructions for Use Technical Support: (US) 1 800 643 1640 (Outside US) +1 858 643 1600 MDSS: +1 858 643 1600 1 INTENDED USE The VerifyNow PRUTest is a whole blood test used in
Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each
Introduction 1.1 Introduction: About 10,500 new cases of acute myelogenous leukemia are diagnosed each year in the United States (Hope et al., 2003). Acute myelogenous leukemia has several names, including
Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty
Round Table: Antithrombotic therapy beyond ACS Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty M. Matsagkas, MD, PhD, EBSQ-Vasc Associate Professor
Causes of Anemia in Patients with Heart Failure. Adriaan Voors, MD, PhD, Cardiologist Professor of Cardiology, UMC Groningen, Netherlands
Causes of Anemia in Patients with Heart Failure Adriaan Voors, MD, PhD, Cardiologist Professor of Cardiology, UMC Groningen, Netherlands Background Anemia is common in patients with CHF Prevalence 15 55%
List of publications
List of publications List of publications List of publications L. van Bloemendaal & J.S. ten Kulve, S.E. la Fleur, R.G. IJzerman, M. Diamant. Effects of glucagonlike peptide 1 on appetite and body weight:
Abnormal Uterine Bleeding: Simple evaluation and management in premenopausal women
Objectives Abnormal Uterine Bleeding: Simple evaluation and management in premenopausal women Provide a framework to evaluate abnormal uterine bleeding (AUB) Review medical and surgical management options
Schlüsselwörter Thrombozytenfunktion, klinische Anwendung, Antithrombotika, Blutungsrisiko
Review Platelet function testing in clinical diagnostics A. R. Rechner Assay Development Hemostasis, Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany Schattauer 2011 79 Keywords Platelet
DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
